‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Martin Shkreli, infamously known as the "Pharma Bro," is facing new scrutiny from regulators for allegedly meddling in the biopharma stock market despite a ban prohibiting him from such activities. This ban was imposed following his previous controversial business practices, including the exorbitant price hike of a lifesaving drug. Regulators are now investigating whether Shkreli’s recent comments and actions have influenced stock prices unfairly, highlighting the ongoing tension between his disruptive influence and regulatory efforts to curb it. This situation underscores the broader challenges regulators face in monitoring and controlling market manipulation in the high-stakes biopharma industry.